Biopharmconsortium Blog

Expert commentary from Haberman Associates biotechnology and pharmaceutical consulting.

Monthly Archives: December 2010

2010: Breakthroughs, Newsmakers, and Deals of the Year

TweetBreakthroughs of the Year As it does every year, Science published its “Breakthrough of the Year” for 2010 in the 17 December issue of the journal. For its “Breakthrough of the Year”, Science chose a non-life science innovation, the first quantum machine. Interestingly, the same issue of Science included a Perspective on biophysicist Britton Chance,…

Will intermediary metabolism be a hot field of biology again?

TweetThe 3 December issue of Science featured a Special Section on metabolism, headed by an introductory article entitled “Metabolism is Not Boring”. Way back in the 1920s through the 1950s, intermediary metabolism was a hot field of biology. This culminated in the awarding of the Nobel Prize in Physiology or Medicine in 1953 to Hans…

Third time’s a charm–FDA Advisory Panel endorses Orexigen’s weight-loss drug Contrave

TweetAs many of you know, this blog has been covering the review of preregistration antiobesity drugs by the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee and by the FDA itself. 2010 was supposed to be the year in which one or more new obesity drugs would be approved by the FDA and reach the market….

GlaxoSmithKline CEO Witty sees the need for smarter R&D innovation

TweetIn a one-page article entitled “Research and develop” in The Economist’s publication “The World in 2011”, GlaxoSmithKline (GSK) CEO Andrew Witty outlined the challenges facing the pharmaceutical industry today, and what to do about them. Mr. Witty began with a familiar catalogue of challenges, including patent expiries and competition from generics, pricing pressure due to…

GlaxoSmithKline stops development of resveratrol drug SRT501

TweetIn statements to Fierce Biotech and to the Myeloma Beacon, GlaxoSmihtKline (GSK) said that it has stopped all development of its proprietary resveratrol formulation SRT501. Thanks also to the “In the Pipeline” blog for the information on the Myeloma Beacon statement. As you all may recall, GSK acquired the sirtuin-pathway specialty company Sirtris (Cambridge, MA)…